Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116 CHF | +1.22% | +4.13% | -7.64% |
Mar. 13 | Medacta Group SA Proposes Distribution | CI |
Mar. 13 | Medacta Group SA Provides Earnings Guidance for the Year 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 31.32 and 27.39 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.13 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.64% | 2.55B | B | ||
-4.91% | 183B | C+ | ||
+0.46% | 108B | C | ||
-3.62% | 67.51B | A | ||
+3.26% | 50.67B | B- | ||
+9.11% | 44.7B | B- | ||
+3.38% | 40.95B | B+ | ||
+6.39% | 26.8B | B | ||
+3.83% | 26.71B | A- | ||
+14.34% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOVE Stock
- Ratings Medacta Group SA